Bristol Myers Squibb (CELG-RI) Change in Cash (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Change in Cash for 18 consecutive years, with -$861.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Cash fell 149.6% year-over-year to -$861.0 million; the TTM figure through Jun 2026 stood at -$3.9 billion (down 161.58% YoY), while the FY2025 annual figure was -$129.0 million, up 88.99% from the prior year.
• Change in Cash declined to -$861.0 million in Q2 2026 per CELG-RI's latest filing, from -$635.0 million in the prior quarter.
• Across five years, Change in Cash topped out at $4.0 billion in Q4 2023 and bottomed at -$5.5 billion in Q4 2025.
• Historically, Change in Cash has averaged -$310.8 million across 5 years, with a median of -$629.0 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Cash sank 2230.26% — and 2024, when it surged 286.35%.
• Bristol Myers Squibb's Change in Cash stood at $1.4 billion in 2022, then surged by 188.82% to $4.0 billion in 2023, then plunged by 37.89% to $2.5 billion in 2024, then plunged by 324.45% to -$5.5 billion in 2025, then jumped by 84.37% to -$861.0 million in 2026.
• Business Quant data shows CELG-RI's Change in Cash at -$861.0 million in Q2 2026, -$635.0 million in Q1 2026, and -$5.5 billion in Q4 2025.